Company / Working Capital
REGENXBIO Inc. Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$163.2M
FY2025
5-year range
$163.2M / $388.4M
FY2021-FY2025
Trend
-6.6%
vs FY2024
Sector context
#179 of 213
Health Care
What the data says
REGENXBIO Inc.'s working capital of $163M is lower than 84% of companies in the Health Care sector (FY2025). Working Capital has declined for 5 consecutive years, from $450M in FY2020 to $163M in FY2025.
Based on SEC 10-K filings.
$163M in FY2025 with a 5-year CAGR of -18.4%.
Declined from $205M to $163M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -17.0%
- 5-Year CAGR
- -18.4%
- 10-Year CAGR
- -
Sector benchmark
Bottom 16% in Health CareTop 84% of 213This company $163.2M Sector average $934.6M
▼
-82.5% below sector average
Key checks
Key Insights
- REGENXBIO Inc.'s working capital has declined for 5 consecutive years.
- 5-year CAGR of -18.4%, indicating a declining trend.
- In FY2025, working capital decreased 6.6% year-over-year.
- Ranks #179 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -2.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $163.2M | -6.6% |
| FY2024 | $174.8M | -14.6% |
| FY2023 | $204.7M | -28.3% |
| FY2022 | $285.5M | -26.5% |
| FY2021 | $388.4M | -13.7% |
| FY2020 | $449.8M | +44.4% |
| FY2019 | $311.4M | -1.4% |
| FY2018 | $315.7M | +105.6% |
| FY2017 | $153.6M | +83.5% |
| FY2016 | $83.7M | -26.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026